Advice

following a full submission:

romosozumab (Evenity®) is accepted for restricted use within NHSScotland.

Indication under review: treatment of severe osteoporosis in postmenopausal women at high risk of fracture.

SMC restriction: to use in patients who have experienced a fragility fracture and are at imminent risk of another fragility fracture (within 24 months).

In a phase III study in post-menopausal women with osteoporosis who were at high risk of fracture, romosozumab for 12 months followed by an oral bisphosphanate reduced the risk of fractures compared with an oral bisphosphonate alone.

This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.

Medicine details

Medicine name:
romosozumab (Evenity)
SMC ID:
SMC2280
Indication:

Treatment of severe osteoporosis in postmenopausal women at high risk of fracture.

Pharmaceutical company
UCB Pharma Ltd
BNF chapter
Musculoskeletal and joint diseases
Submission type
Full
Status
Restricted
Date advice published
09 November 2020